Skip to main content

Research Repository

Advanced Search

Safe nanoengineering and incorporation of transplant populations in a neurosurgical grade biomaterial, DuraGen PlusTM, for protected cell therapy applications

Finch, Louise; Harris, Sarah; Solomou, Georgios; Sen, Jon; Tzerakis, Nikolaos; Emes, Richard D.; Lane, Catherine S.; Hart, Sarah R.; Adams, Christopher F.; Chari, Divya M.

Safe nanoengineering and incorporation of transplant populations in a neurosurgical grade biomaterial, DuraGen PlusTM, for protected cell therapy applications Thumbnail


Authors

Louise Finch

Sarah Harris

Georgios Solomou

Jon Sen

Nikolaos Tzerakis

Richard D. Emes

Catherine S. Lane



Abstract

High transplant cell loss is a major barrier to translation of stem cell therapy for pathologies of the brain and spinal cord. Encapsulated delivery of stem cells in biomaterials for cell therapy is gaining popularity but experimental research has overwhelmingly used laboratory grade materials unsuitable for human clinical use - representing a further barrier to clinical translation. A potential solution is to use neurosurgical grade materials routinely used in clinical protocols which have an established human safety profile. Here, we tested the ability of Duragen Plus™ - a clinical biomaterial used widely in neurosurgical duraplasty procedures, to support the growth and differentiation of neural stem cells- a major transplant population being tested in clinical trials for neurological pathology. Genetic engineering of stem cells yields augmented therapeutic cells, so we further tested the ability of the Duragen Plus™ matrix to support stem cells engineered using magnetofection technology and minicircle DNA vectors- a promising cell engineering approach we previously reported (Journal of Controlled Release, 2016 a \&b). The safety of the nano-engineering approach was analysed for the first time using sophisticated data-independent analysis by mass spectrometry-based proteomics. We prove that the Duragen Plus™ matrix is a promising biomaterial for delivery of stem cell transplant populations, with no adverse effects on key regenerative parameters. This advanced cellular construct based on a combinatorial nano-engineering and biomaterial encapsulation approach, could therefore offer key advantages for clinical translation.

Citation

Finch, L., Harris, S., Solomou, G., Sen, J., Tzerakis, N., Emes, R. D., …Chari, D. M. (2020). Safe nanoengineering and incorporation of transplant populations in a neurosurgical grade biomaterial, DuraGen PlusTM, for protected cell therapy applications. Journal of Controlled Release, 321, 553-563. https://doi.org/10.1016/j.jconrel.2020.02.028

Journal Article Type Article
Acceptance Date Feb 17, 2020
Online Publication Date Feb 19, 2020
Publication Date May 10, 2020
Journal Journal of Controlled Release
Print ISSN 0168-3659
Electronic ISSN 1873-4995
Publisher Elsevier
Volume 321
Pages 553-563
DOI https://doi.org/10.1016/j.jconrel.2020.02.028
Keywords Biomaterial, Combinatorial therapy, DNA minicircles, Genetic engineering, Magnetofection, Mass spectrometry, Neural stem cell, Proteomics, SWATH, Biocompatible Materials, Cell Differentiation, DNA, Humans, Neural Stem Cells, Stem Cell Transplantation, Tis
Publisher URL https://www.ncbi.nlm.nih.gov/pubmed/32087299

Files






You might also like



Downloadable Citations